latest update:
[TrialBase DB]

trial summary · NCT07437963

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy

Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Ganglioneuroblastoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07437963phase PHASE1/PHASE2enrollment 76start 2027-06-25

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in treating patients with neuroblastoma that has come back after a period of improvement (relapsed), that does not respond to treatment (refractory), or that is growing, spreading, or getting worse (progressive) following prior chemoimmunotherapy. Iberdomide is a cereblon-modulating agent. It works by helping the immune system kill tumor cells. Chemoimmunotherapy is chemotherapy combined with immunotherapy. Chemotherapy drugs, such as cyclophosphamide and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with dinutuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Granulocyte-macrophage colony-stimulating factors (GM-CSF), such as sargramostim, may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving iberdomide with chemoimmunotherapy may be safe, tolerable, and/or effective in treating patients with relapsed, refractory, or progressive neuroblastoma following prior chemoimmunotherapy.

Source record: https://clinicaltrials.gov/study/NCT07437963

Facts

registry idNCT07437963
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionRecurrent Ganglioneuroblastoma
sponsorNational Cancer Institute (NCI)
sponsor classNIH
enrollment76
start date2027-06-25
primary completion2029-09-30
completion2029-09-30
results postednot reported

Conditions

  • Recurrent Ganglioneuroblastoma
  • Recurrent Neuroblastoma
  • Refractory Ganglioneuroblastoma
  • Refractory Neuroblastoma

Interventions

  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Computed Tomography
  • Cyclophosphamide
  • Dinutuximab
  • Echocardiography Test
  • FDG-Positron Emission Tomography
  • Iberdomide
  • Magnetic Resonance Imaging
  • Multigated Acquisition Scan
  • Nuclear Radiology Imaging Procedure
  • Sargramostim

1 more in the dataset.

Countries

  • United States

Intervention types: BIOLOGICAL, DRUG, PROCEDURE, RADIATION

Work with this record